Navigation Links
New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection

COLUMBIA, Md., Feb. 20 /PRNewswire/ -- Cylex, Inc., today announced the publication of an independent, peer reviewed, clinical research study in which the level of cellular immune response measured prior to kidney transplantation using the Company's proprietary ImmuKnow(R) immune cell function test was found to identify patients that may be at risk for early acute transplant rejection and unstable kidney function in the first three months following transplantation.

The results of this independent clinical research study, which was authored by members of the kidney transplant programs at Duke University Medical Center (Durham, NC), the University of Minnesota (Minneapolis, MN) and Cedars-Sinai Medical Center (Los Angeles, CA), appeared in an article published in the February 15, 2008 issue of the journal Transplantation.

"Based on our immunosuppression protocol, this study is the first to show that high pre-transplant ImmuKnow values identify recipients at risk for early acute rejection and unstable renal function," said Dr. Nancy L. Reinsmoen of Cedars-Sinai Medical Center and the lead author of the study. "No other innovative parameter we tested showed any such trends or associations."

This study of 126 kidney transplant patients was designed to evaluate the association of a number of immune parameters measured prior to kidney transplant with the occurrence of early acute rejection, unstable kidney function and graft outcome following transplantation. A statistically significant correlation was reported between high pre-transplant levels of cellular immune response, as measured using the ImmuKnow immune cell function test, and early acute transplant rejection as well as unstable kidney function within the first 90 days following kidney transplant.

The authors of the Transplantation article conclude that pre-transplant assessment of donor-specific and nonspecific immune parameters with ImmuKnow "may identify recipients who can benefit from closer clinical and immunological surveillance to allow for tailored immunosuppression and selective intervention aimed at optimizing both short and long-term graft outcome."

"This independent clinical research study from three world renowned transplant centers provides important new evidence regarding the potential clinical utility of the measurement of cell mediated immunity using the ImmuKnow test," said Paul R. Sohmer, MD, acting Chief Executive Officer of Cylex. "We hope that studies such as this will contribute to the growing body of literature regarding the importance of measuring cell mediated immunity in transplantation."

The use of the ImmuKnow assay for identification of patients at risk for kidney rejection, as described in this study, has not been cleared by FDA. The company may use data from this study or similar studies to support a future FDA marketing application for a similar indication.

Cylex's ImmuKnow immune cell function assay detects cell-mediated immunity (CMI) by measuring the concentration of ATP from CD4+ cells following stimulation. The assay is used for the detection of cell-mediated immunity in an immunosuppressed population. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow should be used in conjunction with clinical presentation, medical history, and other clinical indicators when establishing the immune status of a patient.

About Cylex, Inc.

Cylex is a global life science company that develops and manufactures research and in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is an in vitro diagnostic utilized to detect cell mediated immunity in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the country. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers and companion assays.

SOURCE Cylex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
2. China Pharma Appoints Three Independent Non-Executive Directors
3. Amarin Appoints Dr. William Mason as Lead Independent Director
4. Kiwa Fertilizers Pass Independent Tests
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
8. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):